NCT06467825 Effect of Sex on Orthostatic Intolerance and Cardiovascular Response During Lunar Descent and Ascent
| NCT ID | NCT06467825 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Aeronautics and Space Administration (NASA) |
| Condition | Healthy |
| Study Type | INTERVENTIONAL |
| Enrollment | 38 participants |
| Start Date | 2022-08-09 |
| Primary Completion | 2025-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 38 participants in total. It began in 2022-08-09 with a primary completion date of 2025-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of Lunar OI (Orthostatic Intolerance) is to determine if there are differences between males and females in tolerance to and cardiovascular responses during different angles of head-up tilt simulating gravity levels less than or equal to Earth's gravity. Also, this study will determine if a gradient compression garment affects tolerance to tilting and the cardiovascular stress at different tilt angles. Males and females are being identified by biological sex. This will be a two-phased study design. In Phase I we will determine whether there are differences in the development of signs or symptoms of orthostatic intolerance between males and females when tilted head up on a table to different angles to simulate gravity levels that astronauts may experience when landing on or launching from the surface of the Moon. In Phase II, the tilt tests simulating the same gravity levels from Phase I will be repeated, but a custom-made lower-body compression garment will be worn to see if wearing the garment affects the development of orthostatic intolerance. For both study phases, before tilting, a drug will be administered to reduce the amount fluid in the blood (plasma) to levels similar to that experienced by astronauts during spaceflight.
Eligibility Criteria
Inclusion Criteria: • Pass a test subject screening facility modified Air Force Class III physical Exclusion Criteria: * Known allergy to furosemide or sulfa drugs * Currently taking drugs or medications known to adversely interact with furosemide, including but not limited to aspirin, NSAIDs, antibiotics, or immunosuppressant drugs * Systemic diseases or current medications known to influence the cardiovascular system * Renal disease * Type II Diabetes * Pregnant participants will be excluded (a urine pregnancy screen will be made available).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06467825 clinical trial?
This trial is open to participants of all sexes, aged 25 Years or older, up to 55 Years, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06467825 currently recruiting?
Yes, NCT06467825 is actively recruiting participants. Contact the research team at jsc-cardilab@mail.nasa.gov for enrollment information.
Where is the NCT06467825 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT06467825 clinical trial?
NCT06467825 is sponsored by National Aeronautics and Space Administration (NASA). The trial plans to enroll 38 participants.